KAJIAN PUSTAKA KEAMANAN, PENGGUNAAN DAN PENILAIAN GENETIK OBAT GOLONGAN ACEI DAN ARB DALAM PENGOBATAN PASIEN COVID-19 DENGAN KOMORBID PENYAKIT HIPERTENSII
The COVID-19 pandemic is caused by infection with a new type of coronavirus, namely SARS-CoV-2. This virus can infect through its interaction with the angiotensin-converting enzyme 2 (ACE2) receptor. The ACE2 receptor is one of the important components in the renin-angiotensinaldosterone system (R...
Saved in:
Main Author: | |
---|---|
Format: | Final Project |
Language: | Indonesia |
Online Access: | https://digilib.itb.ac.id/gdl/view/61902 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Institut Teknologi Bandung |
Language: | Indonesia |
Summary: | The COVID-19 pandemic is caused by infection with a new type of coronavirus, namely SARS-CoV-2.
This virus can infect through its interaction with the angiotensin-converting enzyme 2 (ACE2)
receptor. The ACE2 receptor is one of the important components in the renin-angiotensinaldosterone system (RAAS) so that the exploitation of the receptor by the SARS-CoV-2 virus can
cause dysregulation in the RAAS system. In an effort to overcome this, various treatment regimens
have been applied to overcome this pandemic. One of them is the use of drugs that inhibit the reninangiotensin-aldosterone system, namely the angiotensin-converting enzyme inhibitors (ACEi) and
angiotensin receptor blockers (ARBs). ACEi drugs work by inhibiting the ACE enzyme, while ARBs
inhibit the angiotensin II type 1 receptor (AT1R). These drugs are often given to individuals with
cardiovascular comorbidities who are at a higher risk of mortality from COVID-19 infection. In
treatment using ACEi and ARB, various clinical responses were obtained in its usage. This may be
due to the presence of genetic polymorphisms in the treatment target gene. The literature review
was carried out by evaluating the use and safety of ACEi or ARB drugs. In addition, genetic
assessment of the ACE and AT1R genes that interact directly with ACEi and ARB drugs was also
carried out. The results of the study show that the use of ACEI/ARB class drugs provides better
clinical outcomes and does not affect the susceptibility of testing positive for COVID-19.
Discontinuation of these drugs may lead to an increased risk of mortality in patients with
comorbidity. The presence of genetic polymorphisms also causes drug interactions with genes that
can affect the efficacy and safety of drugs.
|
---|